According to a new report from Tufts Center for the Study of Drug Development (Tufts CSDD), although many pharmaceutical companies are increasing the pace of new products by improving the efficiency of clinical trial operations, their medium- and long-term success will increasingly depend on their ability to support more efficient research and development (R&D) models.
Preparing for the Zombie Apocalypse and the FDA
In an effort to promote public health awareness, the U.S. Centers for Disease Control and Prevention (CDC) has outlined preparation basics for the zombie apocalypse [1].
Yes, you read that right: zombie apocalypse.
As it turns out, preparing for the zombie apocalypse is similar to preparing for any other disaster: stock up on food, water and medications; have tools and supplies on hand; have items for sanitation and hygiene; etc. The CDC outlines emergency preparedness elsewhere on their website, but apparently no one really wants to read about preparing for a tornado, flood or winter weather. What people do want to read about is the zombie apocalypse. Thus, running with the idea that how you prepare is more important that what you prepare for, CDC went with a tongue-in-cheek, partially no-nonsense discussion of the undead and what happens when they attack.
Grand Rounds: the Impact of Healthcare Reform
Welcome to Grand Rounds: the Impact of Healthcare Reform.
For this edition of Grand Rounds, Vol. 7 No. 11, we’re focusing on the impact of healthcare reform: what are the changes to healthcare delivery, utilization, quality, costs (either as a provider or a patient) and outcomes. After all, these changes affect everyone, whether you’re a patient, a healthcare provider or a biomedical researcher.